Acronym:
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
Cancer Type | All cancers | ||
---|---|---|---|
Trial Type | Treatment | ||
Phase | Phase II | Tumour Stream | Solid tumours |
Age Range | 18 years and older | Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
Sex | Both | Anticipated Start Date | |
Molecular Target | Anticipated End Date |
Cancer Type | All cancers |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | Both |
Molecular Target | |
Tumour Stream | Solid tumours |
Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
Anticipated Start Date | |
Anticipated End Date |
Trial Summary
SGNLVA 005 open label phase 2 study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumours
Lay Summary
Sponsor / Cooperative group
Participating Hospitals
Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
---|---|---|---|---|---|
Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Chris Karapetis | Not Yet Recruiting |